caa a22 4500 469079843 CHVBK 20180323132947.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF00165734 doi (NATIONALLICENCE)springer-10.1007/BF00165734 Effects of gamma-vinyl GABA (vigabatrin) on blood pressure and body weight of hypertensive and normotensive rats [Elektronische Daten] [N. Singewald, A. Pfitscher, A. Philippu] Summary: Inactivation of GABA was inhibited by γ-vinyl GABA (GVG) and the effects of the increased GABA level in the brain on blood pressure and body weight of spontaneously hypertensive rats (SHR) and normotensive rats (WKY) were investigated. When started at the age of 8 weeks or 5 weeks, treatment of SHR and WKY with GVG (150 mg/kg, s.c.) for several weeks did not influence systolic blood pressure. In 1-week old SHR, treatment with GVG (up to 150 mg/kg, s.c.) abolished the rise in blood pressure until animals were 8 weeks old. Thereafter, arterial blood pressure started to increase but it remained distinctly lower than that in untreated animals. When started at the age of 1 week, treatment with GVG for 7 weeks did not influence arterial blood pressure in WKY. GVG delayed increase in body weight in SHR and WKY, irrespective of their age. GVG greatly increased GABA levels in the hypothalamus, frontal cortex, brainstem and rest of the brain in both WKY and SHR. It is concluded that an increase in the GABA level in the brain leads to a delay in the development of hypertension in young SHR. Hence, development of genetic hypertension seems to be susceptible to activation of the GABAergic system in a very early critical phase only. Springer-Verlag, 1992 SHR nationallicence γ-vinyl GABA nationallicence Vigabatrin nationallicence Blood pressure nationallicence Body weight nationallicence Genetic hypertension nationallicence Critical phase nationallicence Singewald N. Institut für Pharmakodynamik und Toxikologie der Universität Innsbruck, Peter-Mayr-Strasse 1, A-6020, Innsbruck, Austria aut Pfitscher A. Institut für Pharmakodynamik und Toxikologie der Universität Innsbruck, Peter-Mayr-Strasse 1, A-6020, Innsbruck, Austria aut Philippu A. Institut für Pharmakodynamik und Toxikologie der Universität Innsbruck, Peter-Mayr-Strasse 1, A-6020, Innsbruck, Austria aut Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 345/2(1992-02-01), 181-186 0028-1298 345:2<181 1992 345 210 https://doi.org/10.1007/BF00165734 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00165734 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Singewald N. Institut für Pharmakodynamik und Toxikologie der Universität Innsbruck, Peter-Mayr-Strasse 1, A-6020, Innsbruck, Austria aut NATIONALLICENCE 700 1- Pfitscher A. Institut für Pharmakodynamik und Toxikologie der Universität Innsbruck, Peter-Mayr-Strasse 1, A-6020, Innsbruck, Austria aut NATIONALLICENCE 700 1- Philippu A. Institut für Pharmakodynamik und Toxikologie der Universität Innsbruck, Peter-Mayr-Strasse 1, A-6020, Innsbruck, Austria aut NATIONALLICENCE 773 0- Naunyn-Schmiedeberg's Archives of Pharmacology Springer-Verlag 345/2(1992-02-01), 181-186 0028-1298 345:2<181 1992 345 210 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer